Activation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9 | Zendy

Diana Gulei | Zendy; Ioana BerindanNeagoe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9

Author(s) -

Diana Gulei,

Ioana BerindanNeagoe

Publication year - 2019

Publication title -

molecular therapy — nucleic acids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.208

H-Index - 59

ISSN - 2162-2531

DOI - 10.1016/j.omtn.2019.05.032

Subject(s) - crispr , genome editing , cas9 , necroptosis , microvesicles , computational biology , biology , computer science , gene , genetics , microrna , programmed cell death , apoptosis

CRISPR/Cas9 has proved its efficiency in vitro, where we now know that this tool can efficiently target specific parts of the genome. These modifications can be used to generate advanced models of human diseases, address specific functions of genes, and develop new therapeutic strategies. Even if these advancements are promising, there are still two great issues associated with CRISPR/Cas9: how we can specifically and safely deliver the editing tool in vivo and how we can address the impossibility of CRISPR/Cas9 to attack all the cells within the targeted pool? This work presents an alternative method for engagement of cell death in cancer cells with immediate application in the preclinical sector and significant translational relevance toward clinics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research